Fortbildung > 3rd Swiss Autoimmune Liver Disease Meeting 2020 20.11.2020 08:50 - 21.11.2020 12:15 4 Credits Online Registration Programm Online Registration October – November 2020 https://www.swissautoimmuneliver.ch/ For more information, please contact : swissaildmeeting@epatocentro.ch Scientific Programme Day 1 – November 20 8:50 -9:00 Welcome and Introduction Andreas Cerny, Switzerland Benedetta Terziroli Beretta -Piccoli, Switzerland Mario Bianchetti, Switzerland 9:00 -10:30 Session 1 Chairs: Andreas Cerny, Switzerland Giorgina Mieli -Vergani, UK 9.00 – 9.20 Genetics in primary biliary cholangitis beyond GWAS Pietro Invernizzi, Italy 9.20 – 09 .40 Th erapeutic developments in autoimmune liver disease s Tom Hemming Karlsen, Norway 09 .40 – 10. 00 There is more than one cause for primary sclerosing cholangitis Richard Thompson, UK 10. 00 – 10.30 30′ Panel discussion and Q&A 10:30-10:45 BREAK October – November 2020 https://www.swissautoimmuneliver.ch/ For more information, please contact : swissaildmeeting@epatocentro.ch 10:45 – 12. 15 Session 2 Chairs: Florian Bihl Diego Vergani 10.45 – 11. 05 Autoimmune hepatitis type 2 Giorgina Mieli -Vergani, UK 11.0 5 – 11. 25 Autoantibodies in autoimmune liver diseases: clinical aspects Luigi Muratori, Italy 11. 25 – 11.45 Beyond guidelines Michael Manns, Germany 11.45 – 12. 15 30′ Panel discussion and Q&A 14.00 – 15:50 Session 3 Chairs: Michael Manns, Germany Pietro Majno -Hurst, Switzerland 14 .00 – 14.20 Living in the Liver, overcoming constraints on T cells Mala Maini, UK 14:20 -14:40 Anti -tumor autologous T -cell therapy for HBV -associated hepatocellular carcinoma Antonio Bertoletti, Singapore 14:40 – 15:00 Animal model of autoimmune liver diseases Urs Christen, Germany 15.00 – 15.20 The impact of gut microbiome on T -cell trafficking Giandomenica Iezzi, Switzerland 15.20 – 15.50 30′ Panel discussion and Q&A October – November 2020 https://www.swissautoimmuneliver.ch/ For more information, please contact : swissaildmeeting@epatocentro.ch Day 2 November 21 9:00 -10:20 Session 4 Cha irs: Andrea De Gottardi, Switzerland Maria Isabel Lucena, Switzerland 9.00 – 9.20 Immunometabolic drugs Michael Trauner, Austria 9.20 – 09 .40 Drug -induced liver injury and autoimmunity Raul Andrade, Spain 9.40 – 10.00 Post -transplant autoimmune liver diseases Diego Vergani, UK 10.00 – 10.20 Gut -liver axis Antonio Moschetta, Italy 10:20 -10:40 BREAK 10: 40 – 11:15 Oral session Chairs: Michael Trauner Andreas Cerny 10: 40 – 10: 50 Antibody -mediated clearance of serum HBsAg has minimal impact on CD8+ T cell responses in mouse models of HBV pathogenesis Valeria Fumagalli, Italy October – November 2020 https://www.swissautoimmuneliver.ch/ For more information, please contact : swissaildmeeting@epatocentro.ch 10: 50 – 11.00 Cell specific transcriptomic analyses reveals a disassociation between treatment response and peripheral markers of immune activation in primary biliary cholangitis Victoria Mulcahy, UK 11.00 – 11.10 Gamma -glutamyl transferase is a prognostic biomarker in primary biliary cholangitis and improves risk stratificatio n based on the alkaline phosphatase Alessio Gerussi, Italy 11.10 – 11.20 The PBC Foundation App: What Have We Learned and What Should We Do Next? Robert Mitchell -Thain, UK 11.20 – 11.50 30′ Panel discussion and Q&A 11.50 – 12.00 What have we learned and what should we do next Pietro Invernizzi, Italy 12.00 – 12.15 Concluding remarks Andreas Cerny , Switzerland Donna Cryer, President & CEO – The Global Liver Institute, USA Benedetta Terziroli Beretta -Piccoli , Switzerland